Advanced search
Publication Cover
Journal of Medical Economics Volume 18, 2015 - Issue 6
Submit an article Journal homepage
1,190
Views
12
CrossRef citations to date
0
Altmetric
Review

Cost per remission and cost per response with infliximab, adalimumab, and golimumab for the treatment of moderately-to-severely active ulcerative colitis

Kabirraaj ToorRedwood Outcomes, Vancouver, British Columbia, Canada, and School of Population and Public Health, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada
,
Eric DruytsRedwood Outcomes, Vancouver, British Columbia, Canada, and Department of Medicine, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada
,
Jeroen P. JansenRedwood Outcomes, Vancouver, British Columbia, Canada, and Department of Public Health and Community Medicine, Tufts University, Boston, MA, USA
&
Kristian ThorlundRedwood Outcomes, Vancouver, British Columbia, Canada, Department of Clinical Epidemiology & Biostatistics, McMaster University, Hamilton, Ontario, Canada, and Stanford Prevention Research Center, Stanford University, Stanford, CA, USACorrespondence[email protected]
Pages 437-446 | Accepted 23 Jan 2015, Published online: 18 Feb 2015

Citations (12)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Sean Stern, Alexandra J. Ward, Catherine Saint-Laurent Thibault, Fernando Camacho, Elham Rahme, Dominik Naessens, Guy Aumais, Edmond-Jean Bernard, Raymond Bourdages, Albert Cohen, Pierre Pare & Peter Dyrda. (2018) Cost-effectiveness of golimumab for the treatment of patients with moderate-to-severe ulcerative colitis in Quebec using a patient level state transition microsimulation. Journal of Medical Economics 21:1, pages 27-37.
Read now

Articles from other publishers (11)

Vipul Jairath, Russell D. Cohen, Edward V. LoftusJr.Jr., Ninfa Candela, Karen Lasch & Bob G. Schultz. (2022) Evaluating cost per remission and cost of serious adverse events of advanced therapies for ulcerative colitis. BMC Gastroenterology 22:1.
Crossref
Pascal Juillerat, Maude Martinho Grueber, Roseline Ruetsch, Giulia Santi, Marianne Vuillèmoz & Pierre Michetti. (2022) Positioning biologics in the treatment of IBD: A practical guide – Which mechanism of action for whom?. Current Research in Pharmacology and Drug Discovery 3, pages 100104.
Crossref
Wei Niu, Xiaoqing Chen, Ruling Xu, Huimin Dong, Fuyan Yang, Yun Wang, Zhenhai Zhang & Jianming Ju. (2021) Polysaccharides from natural resources exhibit great potential in the treatment of ulcerative colitis: A review. Carbohydrate Polymers 254, pages 117189.
Crossref
Mattias Neyt, Annick Christiaens, Marina Aloi, Lissy de Ridder, Nicholas M Croft, Sibylle Koletzko, Arie Levine, Dan Turner, Richard K Russell, Frank M Ruemmele & Gigi Veereman. (2021) Identifying Health Economic Considerations to Include in the Research Protocol of a Randomized Controlled Trial (the REDUCE-RISK Trial): Systematic Literature Review and Assessment. JMIR Formative Research 5:1, pages e13888.
Crossref
Abhinav Vasudevan, Peter R Gibson & Daniel R Van Langenberg. (2019) Systematic Review: Cost-effective Strategies of Optimizing Anti-tumor Necrosis and Immunomodulators in Inflammatory Bowel Disease. Inflammatory Bowel Diseases 25:9, pages 1462-1473.
Crossref
Gabriele Dragoni, Marco Le Grazie, Beatrice Orlandini & Francesca Rogai. (2018) Golimumab in inflammatory bowel diseases: present and future scenarios. Clinical Journal of Gastroenterology 12:1, pages 1-9.
Crossref
Matteo Ruggeri & Francesca Romana Rolli. (2019) Cost per response/remission in biologics available in Italy for the treatment of TNF-α inhibitors-naïve patients with ulcerative colitis. Global & Regional Health Technology Assessment: Italian; Northern Europe and Spanish 2019, pages 228424031882243.
Crossref
Lachaine Jean, Miron Audrey, Catherine Beauchemin & on behalf of the iGenoMed Consortium. (2018) Economic Evaluations of Treatments for Inflammatory Bowel Diseases: A Literature Review. Canadian Journal of Gastroenterology and Hepatology 2018, pages 1-14.
Crossref
Ewa Stawowczyk & Paweł Kawalec. (2017) A Systematic Review of the Cost-Effectiveness of Biologics for Ulcerative Colitis. PharmacoEconomics 36:4, pages 419-434.
Crossref
Jan Wehkamp & Eduard F. Stange. (2018) Recent advances and emerging therapies in the non-surgical management of ulcerative colitis. F1000Research 7, pages 1207.
Crossref
Won Moon. (2016) Golimumab Therapy in Ulcerative Colitis. The Korean Journal of Gastroenterology 67:2, pages 64.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.